Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Scott D Solomon

Showing results (501-510 of 1,211) with videos related to

Pageof 122
Sort By:
Cardiovascular Research|November 17, 2025
Obesity, aldosterone, and natriuretic peptide in patients with heart failure and reduced ejection fractionShingo Matsumoto, Jawad H Butt, Kieran F Docherty, et al.
European Journal of Heart Failure|January 25, 2024
Efficacy and safety of CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: Rationale and design of the HF-REVERT trialJohann Bauersachs, Scott D Solomon, Stefan D Anker, et al.
JAMA Cardiology|September 27, 2023
Health and Economic Evaluation of Sacubitril-Valsartan for Heart Failure ManagementAnkeet S Bhatt, Muthiah Vaduganathan, Brian L Claggett, et al.
Circulation. Heart Failure|May 17, 2021
Association Between Angiotensin Receptor-Neprilysin Inhibition, Cardiovascular Biomarkers, and Cardiac Remodeling in Heart Failure With Reduced Ejection FractionSean P Murphy, Margaret F Prescott, Alan S Maisel, et al.
Journal of the Renin-Angiotensin-Aldosterone System : JRAAS|February 16, 2012
Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE)Hans-Henrik Parving, Barry M Brenner, John J V McMurray, et al.
European Journal of Heart Failure|February 4, 2022
Effects of sacubitril/valsartan versus valsartan on renal function in patients with and without diabetes and heart failure with preserved ejection fraction: insights from PARAGON-HFAlexander Peikert, Muthiah Vaduganathan, Finnian Mc Causland, et al.
Journal of Cardiac Failure|December 19, 2024
Effectiveness of Virtual Care Team Guided Management of Hospitalized Patients with HFrEF by EthnicityJohn H Bertot, Anubodh S Varshney, Alea Moscone, et al.
Diabetes, Obesity & Metabolism|August 14, 2023
Estimated lifetime benefit of novel pharmacological therapies in patients with type 2 diabetes and chronic kidney disease: A joint analysis of randomized controlled clinical trialsHiddo J L Heerspink, Priya Vart, Niels Jongs, et al.
Circulation. Heart Failure|May 24, 2011
Dyssynchrony, contractile function, and response to cardiac resynchronization therapyDorit Knappe, Anne-Catherine Pouleur, Amil M Shah, et al.
JACC. Heart Failure|April 12, 2014
Impact of cardiovascular events on change in quality of life and utilities in patients after myocardial infarction: a VALIANT study (valsartan in acute myocardial infarction)Eldrin F Lewis, Yanhong Li, Marc A Pfeffer, et al.
Pageof 122

Showing results (501-510 of 1,211) with videos related to

Sort By:
Pageof 122
Cardiovascular Research|November 17, 2025
Obesity, aldosterone, and natriuretic peptide in patients with heart failure and reduced ejection fractionShingo Matsumoto, Jawad H Butt, Kieran F Docherty, et al.
European Journal of Heart Failure|January 25, 2024
Efficacy and safety of CDR132L in patients with reduced left ventricular ejection fraction after myocardial infarction: Rationale and design of the HF-REVERT trialJohann Bauersachs, Scott D Solomon, Stefan D Anker, et al.
JAMA Cardiology|September 27, 2023
Health and Economic Evaluation of Sacubitril-Valsartan for Heart Failure ManagementAnkeet S Bhatt, Muthiah Vaduganathan, Brian L Claggett, et al.
Circulation. Heart Failure|May 17, 2021
Association Between Angiotensin Receptor-Neprilysin Inhibition, Cardiovascular Biomarkers, and Cardiac Remodeling in Heart Failure With Reduced Ejection FractionSean P Murphy, Margaret F Prescott, Alan S Maisel, et al.
Journal of the Renin-Angiotensin-Aldosterone System : JRAAS|February 16, 2012
Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE)Hans-Henrik Parving, Barry M Brenner, John J V McMurray, et al.
European Journal of Heart Failure|February 4, 2022
Effects of sacubitril/valsartan versus valsartan on renal function in patients with and without diabetes and heart failure with preserved ejection fraction: insights from PARAGON-HFAlexander Peikert, Muthiah Vaduganathan, Finnian Mc Causland, et al.
Journal of Cardiac Failure|December 19, 2024
Effectiveness of Virtual Care Team Guided Management of Hospitalized Patients with HFrEF by EthnicityJohn H Bertot, Anubodh S Varshney, Alea Moscone, et al.
Diabetes, Obesity & Metabolism|August 14, 2023
Estimated lifetime benefit of novel pharmacological therapies in patients with type 2 diabetes and chronic kidney disease: A joint analysis of randomized controlled clinical trialsHiddo J L Heerspink, Priya Vart, Niels Jongs, et al.
Circulation. Heart Failure|May 24, 2011
Dyssynchrony, contractile function, and response to cardiac resynchronization therapyDorit Knappe, Anne-Catherine Pouleur, Amil M Shah, et al.
JACC. Heart Failure|April 12, 2014
Impact of cardiovascular events on change in quality of life and utilities in patients after myocardial infarction: a VALIANT study (valsartan in acute myocardial infarction)Eldrin F Lewis, Yanhong Li, Marc A Pfeffer, et al.
Pageof 122